IDT Australia (BM9) Stock Overview

Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. More details

BM9 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Earnings have declined by 39.2% per year over past 5 years

Does not have a meaningful market cap (€9M)

BM9 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW479,582 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

479,582 investors already sharing narratives

View all narratives

IDT Australia Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for IDT Australia
Historical stock prices
Current Share Price	AU$0.01
52 Week High	AU$0.01
52 Week Low	AU$0.01
Beta	0.94
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	BM9	DE Pharmaceuticals	DE Market
7D	0%	-2.0%	0.1%
1Y	n/a	36.5%	-0.5%

Return vs Industry: Insufficient data to determine how BM9 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BM9 performed against the German Market.

Price Volatility

Is BM9's price volatile compared to industry and market?
BM9 volatility
BM9 Average Weekly Movement	0%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	5.3%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine BM9's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1975	n/a	n/a	idtaus.com.au

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides medicinal cannabis and psychedelics; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms.

IDT Australia Limited Fundamentals Summary

How do IDT Australia's earnings and revenue compare to its market cap?
BM9 fundamental statistics
Market cap	€8.90m
Earnings (TTM)	-€3.75m
Revenue (TTM)	€11.63m

0.8x

P/S Ratio

-2.4x

P/E Ratio

Is BM9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BM9 income statement (TTM)
Revenue	AU$19.00m
Cost of Revenue	AU$7.71m
Gross Profit	AU$11.30m
Other Expenses	AU$17.43m
Earnings	-AU$6.13m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.014
Gross Margin	59.46%
Net Profit Margin	-32.26%
Debt/Equity Ratio	48.5%

How did BM9 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/23 23:29
End of Day Share Price	2026/07/23 00:00
Earnings	2025/12/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IDT Australia Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Shane Storey	Canaccord Genuity Historic (Wilsons Advisory and Stockbroking Ltd.
Scott Power	Morgans Financial Limited

IDT Australia LimitedDB:BM9 Stock Report